RxDoctor Payments Data

Jennifer Mulvey Fitzgerald, NP

Family · East Setauket, NYNPI 1023261849

Payments from drug & device makers

$2,988in general payments, 2019–2025

Across 36 payments — averaging $82.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$2K
  • Mannkind Corporation$368
  • Abbott$338
  • Sanofi-aventis U.S. LLC$243
  • Xeris Pharmaceuticals, Inc.$142
  • Novo Nordisk$124
  • plus $181 from 4 others

What the payments were for

  • Food & beverage$2,988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,988 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$80,051
Medicare patients
271
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$206,918
MounjaroTirzepatide58$95,364
JardianceEmpagliflozin34$41,186
JanuviaSitagliptin Phosphate36$35,415
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$21,773
Tresiba Flextouch U-200Insulin Degludec23$17,493
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$12,086
Novolog FlexpenInsulin Aspart51$11,591
Lantus SolostarInsulin Glargine,hum.Rec.Anlog70$9,689
Humalog Kwikpen U-100Insulin Lispro29$8,520
Tresiba Flextouch U-100Insulin Degludec11$6,315
Nano 2nd Gen Pen NeedlePen Needle, Diabetic39$5,259
Ultra-Fine Short Pen NeedlePen Needle, Diabetic26$5,090
SynthroidLevothyroxine Sodium35$3,148
Levothyroxine Sodium134$2,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$124$206,918126 claims
Lilly USA, LLCMounjaro$120$95,36458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →